Strategic Narrative · Draft 1.0
Talk with us
One hospitalized patient. A dozen metabolic signals, moving at once. GlytecOne reads them together, connects the conditions driving your most serious and most expensive failures, and surfaces the decision that needs a clinician now.
This is Barbara Parker. 64, a grandmother of three, two days out of heart surgery.Overnight, Barbara's signals drift. Her care team gets one clear finding ... in time to act.Barbara goes home Thursday. Tolerating the gap, across a whole system, looks like this instead.IDNs and payviders running 1,000+ beds across 5 to 15 hospitals, accountable for quality and cost at scale ... and standardizing their enterprise EHR to reduce variability.
Teams working to cut preventable harm and get ahead of CMS glycemic eCQM reporting ... who need real-time visibility, not another retrospective report.
Leadership that treats whole-patient care as organizational change, not a software purchase ... with a champion who carries it across quality, nursing, and pharmacy.
A single hospitalized patient can have four or five metabolic conditions moving at the same time. Each one is watched by a different system, and escalated to a different specialist. Nothing watches how those conditions feed each other, and no one is accountable for the patient as a whole.
This is signal-by-signal care. Every tool can prove it did its one job, and the most dangerous, most expensive deterioration grows in the gaps between them ... in plain sight.
GlytecOne assembles the entire metabolic picture in one place, shows how the conditions connect, and gives every clinician the same complete view. A patient who used to be watched in pieces is finally seen as a whole ... and the software recommends, while the clinician decides. Always.
Each one watches a single number and pages someone when a threshold trips. Nobody owns what happens between the alarms ... and the deterioration lives exactly there.
Powerful, general, and empty on day one. You bring the clinical model, the build team, and the months. The intelligence is your job.
Purpose-built for the whole metabolic patient, working day one, clinician in the loop on every decision ... and the only one of the three that is FDA-cleared to act on what it sees, dosing insulin safely at the bedside.
Turnkey · clinician-in-the-loop · FDA-cleared dosingOn a dashboard they are B. Parker, E. Clark, D. Brooks, and P. Singh. At home they are Barbara, Eleanor, David, and Priya ... and the whole patient is a whole person.
Barbara, 64grandmother of three · heart surgery, day 2
Eleanor, 72retired teacher · watched for early sepsis
David, 58carpenter · kidneys under pressure
Priya, 45mother of two · seven active medications
Marcus, 66coaches Little League · heart failure, day 4Start with the patient, because that is what matters. When one system assembles the whole metabolic picture, the finding that matters surfaces while there is still time to act ... and the clinician, not the software, makes the call. That is better care, and it is what a clinical leader evaluates first.
The money follows directly. Hospitals are paid a fixed amount per diagnosis. When the picture comes late, the stay runs longer, the workup grows, and the hospital absorbs the difference. This is not a savings claim ... it is revenue leakage that is already occurring, and across a health system it reaches into the tens of millions a year. Catch the picture earlier and that leakage stays in the building, quarter after quarter.
Deterioration caught in the drift. Decisions routed while there is still time to change the outcome. A care team freed from alarm noise to do the work they trained for.
Once leaders see the whole patient in real time, they do not go back. What was tolerated as normal variation becomes clearly preventable risk.
We model what unmanaged metabolic deterioration is costing your system today ... your admissions, your case mix, a defensible number your CFO can pressure-test.
Go live on a single unit. Count the catches, the routed decisions, and the days of stay ... measured against your own baseline, not a brochure.
Roll out system-wide on the platform you already trust for insulin dosing, and grow into the whole-patient roadmap together.
For more than 20 years, we have been the FDA-cleared leader in insulin dosing, trusted by roughly 65 hospital systems. Dosing insulin safely is not a single-number problem ... it means accounting for everything moving a patient's metabolism at once. We built an engine to do that, and that engine is how we learned to see the whole patient. GlytecOne is the same intelligence, aimed at everything it was already watching.
A published customer study measured a 3.18-day reduction in length of stay with system-wide glycemic management.
Attribution being finalized in the proof ledger.Glycemic control is shown to improve survival in patients who become septic ... one of the strongest evidence lines in the field.
Claim language to be locked with clinical sign-off.Every figure the final story ships with carries its own row: the number, the customer, the source, and the permission to publish it.
The discipline that keeps the narrative unimpeachable.Glytec is the largest insulin-dosing company in the United States. The next chapter is the whole patient ... and it is a world bigger than the company you already know.
Talk with us
